Completed PHASE2 INTERVENTIONAL 1-arm NCT03397953

Vinorelbine for Recurrent ACLC

Phase II Study of Vinorelbine for Children With Recurrent Anaplastic Large Cell Lymphoma

Sponsor: Children's Cancer Group, China

Conditions Anaplastic Large Cell Lymphoma Vinorelbine

Interventions Vinorelbine

Updated 8 times since 2018 Last updated: Jul 23, 2022 Started: Nov 30, 2016 Primary completion: Jul 31, 2022 Completion: Jul 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anaplastic Large Cell Lymphoma and Vinorelbine and is currently completed. Children's Cancer Group, China leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2021 — Sep 2022 [monthly]

Unknown Status PHASE2
Oct 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Oct 2020 [monthly]

Recruiting PHASE2
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Feb 2018 — Mar 2018 [monthly]

Recruiting PHASE2

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Cancer Group, China

Data source: Children's Cancer Group, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China